X eroderma pigmentosum (XP) is a rare, autosomal recessive disorder associated with mutations in genes involved in the nucleotide excision repair pathway. Xeroderma pigmentosum can be caused by mutations in 7 nucleotide excision repair genes (XPA-XPG [XPA, OMIM 611153; XPB excision repair, complementing defective, in Chinese hamster, 3, ERCC3, OMIM 133510; XPC, OMIM 613208; XPD, excision repair, complementing defective, in Chinese hamster, 2, ERCC2, OMIM 126340; XPE, DNA damage-binding protein 2, DDB2, OMIM 600811; XPF,e x cision repair, complementing defective, in Chinese hamster, 4, ERCC4, OMIM 133520; XPG, excision repair, complementing defective, in Chinese hamster, 5, ERCC5, OMIM 133530]) and in the POLH gene (POLH XP variant, polymerase, DNA, ETA, OMIM 603968), a bypass polymerase, and is characterized by the inability to repair UV-induced and chemically induced DNA damage. 1 Patients with XP are usually clinically identified owing to severe sun sensitivity after minimum sun exposure, freckle-like (lentiginous) pigmentation on sun-exposed skin before 2 years of age, and premature development of many skin cancers. Some patients (approximately 20% in the United States) also have early onset of progressive neurologic degeneration. 1, 2 Patients with XP younger than 20 years have a 10 000-fold increased risk of sunlight-induced skin cancer. 2 The frequency of XP in western Europe is clinically estimated to be about 1 in 1 million individuals. 3 Clinical diagnosis is often confirmed by DNA sequencing of the genes known to cause XP. With the growing emphasis on using genomic sequencing to assess risk of disease, we investigated the frequency of XP using data from large genomic databases. To identify and analyze the prevalence of recessive germline mutations associated with XP, we mined 4 databases: the Human Gene Mutation Database, 4 the Genome Aggregation Database (gnomAD) 5 ; an independent database from the National Institutes of Health (NIH), National Cancer Institute Division of Cancer Epidemiology and Genetics (DCEG) [6] [7] [8] ; and an Inova Hospital Study database. 9 We also examined our cohort of patients at the NIH with XP. 2 We sought to compare the genetically estimated prevalence of disease, based on the frequency of known pathogenic mutations in heterozygous carriers from the general population, with the reported prevalence of the clinically observed and diagnosed XP phenotype. The clinical pathogenicity of the mutations associated with XP were confirmed by identifying patients in the literature who harbored these mutations, who received a diagnosis of clinical XP, and who underwent a laboratory assessment confirming reduced DNA repair. We found high allele frequencies for several XP genetic variants. This finding suggests that there should be thousands of patients who are homozygous for missense or nonsense mutations in XPF, XPC, and other genes causing XP and should, consequently, express the clinical XP phenotype. It could also suggest that our understanding and interpretation of the variants associated with these human diseases is incorrect. Could these genetic variants be a risk factor in some patients with multiple skin cancers with subclinical features of XP?
Methods
From January 1, 2017, to May 4, 2018, we searched the Human Gene Mutation Database Professional 4 and our cohort at the NIH 2 to identify all germline mutations with a reported association with a clinically recognized XP phenotype. The patients at the NIH were examined under a protocol approved by the National Cancer Institute Institutional Review Board. All patients and/or parents provided written informed consent. The Human Gene Mutation Database includes mutations from 7791 genes representing most of the published mutations responsible for human inherited diseases. The Human Gene Mutation Database does not include somatic or mitochondrial mutations. We focused exclusively on the missense and nonsense mutations to estimate the frequency of XP because those mutations cause changes in DNA that result in an amino acid change or a premature stop codon and are likely to be pathogenic. Also, a substantial portion of these mutations had allele frequencies listed in gnomAD.
5 GnomAD provides allele frequencies of human genomic variants and mutations and includes 123 000 exome sequences from 8 different world subpopulations. We used gnomAD to represent the general population for our determinations. We investigated the consistency of some of these allele frequencies by analyzing control data from a separate independent exome sequencing database from the National Cancer Institute DCEG database. 
.
Results

Mutations Associated With XP
We identified a total of 156 missense and nonsense mutations associated with XP ( Table 1;eTable1intheSupplement) in8 XP genes (XPA-G and POLH) using the Human Gene Mutation Database 4 and our patients at the NIH. 2 The XPD (ERCC2) gene had the most mutations associated with XP (32 reported), while XPB (ERCC3) had the least mutations associated with XP (2 reported). (Table 2 ; eTable 2 in the Supplement). These mutations were identified predominantly in individuals of African descent. All 7 individuals reported as homozygous for this mutation in gnomAD were of African ancestry. Before estimating the expected number of patients, we tested the Hardy-Weinberg equation using the data reported in gnomAD and the other databases to estimate the number of homozygotes expected to be in each database. We estimated 2.28 XPF p.P379S homozygotes would be present in gnomAD, 0.03 XPF p.P379S homozygotes would be present in the DCEG database, and 0.02 XPF p.P379S homozygotes would be present in the Inova Hospital Study database. The actual reported number of homozygotes was 4 in gnomAD, 0 in the DCEG database, and 0 in the Inova Hospital Study database ( Table 2 ). The comparability of the number of estimated homozygotes and observed homozygotes confirmed the reasonableness of using the Hardy-Weinberg equation to estimate the number of homozygotes present using the US population.
Mutations in Exome Databases
Estimations of XP Mutation Prevalence in the US Population
We used the allele frequencies of XPF p.P379S and the reported population of the United States (3.23 × 10 8 )( http:// www.worldometers.info/) to estimate the number of genetically homozygous patients expected to express the XP phenotype. We estimated that there should be approximately 5300 patients who are homozygous for the XPF p.P379S mutation in the United States (Table 2 ). In contrast, only 3 patients who were homozygous or compound heterozygous for the XPF p.P379S mutation were identified as affected in the world literature (Table 3) . 12,13,16 Using a similar approach, Fassihi et al 12 noted that this XPF p.P379S mutation was present at a frequency of 0.3% in the Single Nucleotide Polymorphism database. They state, "this estimate implies that there might be a significant cohort of UVR-sensitive individuals not recognized as having XP, but homozygous for this mutation." 12(pE1242) We found a similar disparity for the second most common XP associated mutation, XPC p. P334H, which was estimated to be present in about 3000 people in the United States. Only 1 patient with this mutation was reported in the literature (Table 3) .
19-22
Phenotypes of People With XP Mutations
The 15 patients with XP reported in the literature 12-22 with at least 1 of 3 relatively frequent mutations associated with XP, XPF p.P379S, XPC p.P334H, and XPF p.R779W, were confirmed as receiving a clinical diagnosis of XP and having reduced DNA repair (Table 3) . Their clinical features varied. Thirteen of these patients were reported to have marked sun sensitivity, 11 had abnormal freckling (lentigines), and 4 had skin cancer. Of the 3 patients with XP with the XPF p.P379S mutation, an 18-year-old man (patient XP72BR) was homozygous for p.P379S. He had several episodes of severe sunburn as a child. He had few lentigines, no skin cancer, and no neurologic or ocular abnormalities. His cells had decreased DNA repair (unscheduled DNA synthesis after UV
damage [UDS], 35% of normal).
12 A 23-year-old man (patient XP32BR) was reported as being a compound heterozygous with XPF p.P379S and p.R589W. Since infancy, he had severe sunburns with minimal sun exposure, resulting in a diagnosis of XP at 7 years of age. He had a pale complexion and no neurologic abnormalities. His cells had decreased DNA repair (UDS, 18% of normal). 12 The third patient (patient XP7NE) was reported as harboring XPF p.P379S and a silent allele. 13, 16 This patient was a 28-year-old man with decreased DNA repair (UDS, 30% of normal), a history of severe sunburns, numerous large freckles on the back of his hands and shoulders, and no skin cancer 16 (A. Lehmann, PhD, C. Arlett, PhD, and H. Fassihi, MD, written communication, September 2018). XPC p.P334H was the second most common mutation associated with XP. However, there was only 1 patient (patient XP1MI) reported in the literature with this mutation.
19-22 She was homozygous for the mutation, born with low birth weight and microcephaly and had reduced DNA repair (UDS, 13% of normal). This patient (with cell lines CRL 1333 and GM02096) was reported as a 17-year-old African American girl who had both XP and systemic lupus erythematosus. 19 She was examined at the NIH at 18 years of age, where the diagnoses of both XP and systemic lupus erythematosus were confirmed. She had abnormalities of her skin typical for XP (hypopigmentation and hyperpigmentation), multiple skin cancers, and severe photodamage to her eyes. Her IQ was previously reported as being in the range of persons with intellectual disability (mental retardation), and it was noted that her IQ may have been affected by her limited vision and other conditions. The diagnosis of systemic lupus erythematosus was confirmed, with several swollen joints making it difficult for her to write and walk and with positive blood test results for lupus anticoagulant and antinuclear antibody. This patient died at 37 years of age. Two of the 11 patients with XP and the XPF p.R799W mutation were reported as homozygous, and 9 were compound heterozygotes.
12-18 All had reduced DNA repair. Three of these patients had skin cancer, and 9 had adult-onset severe neurodegeneration (Table 3) . We also found 6 other mutations associated with XP with frequencies greater than 10 These 6 mutations plus the 2 mutations in XPF (ERCC4) and the 1 mutation in the XPC gene have a combined population frequency of about 1% and account for 93% of the frequency of the 65 variant alleles associated with XP in gnomAD (eTable 2 in the Supplement).
Discussion
Extensive work has focused on the "genotype-phenotype correlation," which usually has meant assessing phenotype and then looking for an underlying genotype. Much of our understanding of the association between clinical disease and underlying genetics has been based on this approach, and it has resulted in an assumption that certain mutations equate with specific clinical manifestations. However, to our knowledge to date, there are few data on the reverse approach: understanding the spectrum of clinical manifestations of variants and how they are associated with penetrance and expressivity, especially when those variants may cause subclinical manifestations of disease. Large genomic databases now allow for the estimation of the frequency of variant alleles. Measuring genotypes in a population and then looking for expected phenotypes have resulted in a surprising discordance: an absence of patients expected to be affected. This finding remains true even with the extensive data processing, variant calling, quality control, and filtering performed on the data in gnomAD.
5
Our investigation provided unexpected information. The population estimations based on the allele frequencies of the 9 most frequent mutations associated with XP suggest that, based on prevalence of genotype, there should be substantially more cases of XP than have been identified clinically. One of the least common genes reported to cause XP, XPF (ERCC4), had mutations associated with XP with notably high frequencies in 3 independent databases (2 with verified normal populations). The frequency of the XPF p.P379S mutation in gnomAD suggests that there should be about 5300 patients in the United States who are homozygous for this mutation (Table 2 ). These numbers were estimated using the US population of 323 million. This estimation was vastly contrasted with only 3 patients being identified in the literature as harboring at least 1 XPF (ERCC4) p.P379S mutation (Table 3) . Similarly, the XPC p.P334H mutation frequency in gnomAD would estimate that about 3000 individuals in the United States are homozygous for this mutation, and only 1 individual was reported in the literature ( Table 2 ). The combined frequency of the 65 variants associated with XP listed in gnomAD is 1.13% (Table 1 ; eTable 2 in the Supplement). This frequency would imply that more than 9000 individuals are homozygous for these variants in the United States (Table 2 ). With the high frequencies of skin cancer in the general population, homozygous carriers of these mutations may represent a subgroup of individuals with a mild or subclinical XP phenotype. If these patients could be identified early, strict sun avoidance and surveillance measures could reduce the morbidity and mortality rates of skin cancer.
These reported clinical and laboratory observations demonstrated the clinically associated pathogenicity of these mutations. However, the clinical features of patients with these reported mutations challenge our approach to recognizing the clinical profile of XP, which currently is strongly associated with sun sensitivity and a 10 000-fold increased risk of skin cancer. Although the 14 patients with XPF (ERCC4) mutations ranged in age from 18 to 62 years, only 3 of them received a diagnosis of skin cancer. Neurologic degeneration in patients with XP with mutations in the XPA or XPD (ERCC2) genes typically has an onset in the first decade of life. In contrast, 9 of 11 patients harboring the XPF (ERCC4) p.R799W mutation had a different phenotype, with adult-onset neurologic degeneration with onset as late as 47 years of age (Table 3) . Xeroderma pigmentosum should be considered in patients with sun sensitivity, premature development of many skin cancers (especially of more than 1 type), freckle-like (lentiginous) pigmentary abnormalities or poikilodermatous skin changes, and/or undiagnosed neurologic degeneration. 1 
Limitations
There is a marked discrepancy between the data in these genomic databases and the reported clinical prevalence of recessive XP. It is possible that we are not identifying some homozygous patients owing to a mild or varied phenotype, incomplete penetrance of mutated alleles, modifier genes, fetal loss, or late onset of clinical manifestations such as neurodegeneration. The penetrance of XP-type mutations may depend on many factors, including skin type, the rate at which tumorigenic mutations (eg, TP53) accumulate, possible suppressor mutations, compensating levels of gene expression, and levels of patients' sun exposure. Unfortunately, the DNA samples in gnomAD were collected in a manner that does not permit obtaining clinical information on donors with variations of interest. Mutations in the XPF endonuclease have been reported to result in diverse clinical manifestations, including Cockayne syndrome and Fanconi anemia in addition to XP. 28 
